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Abstract
Together with mesangial cells, glomerular endothelial cells and the basement membrane,
podocytes constitute the glomerular filtration barrier (GFB) of the kidney. Podocytes play a
pivotal role in the progression of various kidney-related diseases such as glomerular sclero-
sis and glomerulonephritis that finally lead to chronic end-stage renal disease. During podo-
cytopathies, the slit-diaphragm connecting the adjacent podocytes are detached leading to
severe loss of proteins in the urine. The pathophysiology of podocytopathies makes podo-
cytes a potential and challenging target for nanomedicine development, though there is a
lack of known molecular targets for cell selective drug delivery. To identify VCAM-1 as a
cell-surface receptor that is suitable for binding and internalization of nanomedicine carrier
systems by podocytes, we investigated its expression in the immortalized podocyte cell
lines AB8/13 and MPC-5, and in primary podocytes. Gene and protein expression analyses
revealed that VCAM-1 expression is increased by podocytes upon TNFα-activation for up
to 24 h. This was paralleled by anti-VCAM-1 antibody binding to the TNFα-activated cells,
which can be employed as a ligand to facilitate the uptake of nanocarriers under inflamma-
tory conditions. Hence, we next explored the possibilities of using VCAM-1 as a cell-surface
receptor to deliver the potent immunosuppressant rapamycin to TNFα-activated podocytes
using the lipid-based nanocarrier system Saint-O-Somes. Anti-VCAM-1-rapamycin-SAINT-
O-Somes more effectively inhibited the cell migration of AB8/13 cells than free rapamycin
and non-targeted rapamycin-SAINT-O-Somes indicating the potential of VCAM-1 targeted
drug delivery to podocytes.
Introduction
Kidney glomeruli are composed of four major components namely mesangial cells, fenestrated
endothelium, glomerular basement membrane (GBM), and podocytes. These latter cells
form the glomerular filtration barrier (GFB) of the kidney. Mesangial cells, present in the
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interstitium between the glomerular endothelial cells, are indirectly involved in the filtration
process by controlling the glomerular surface area [1]. The glomerular endothelium is lined
with 70–100 nm fenestrations which are actively involved in filtration [1]. The fenestrated
endothelium is attached to one side of the GBM, which contain pores of around 250–350 nm.
The GBM is sandwiched on the proximal side by visceral epithelial cells called podocytes. The
adjacent podocytes are connected by slit diaphragms with a width of around 40 nm, forming
podocyte foot processes mainly involved in filtration of proteins [1]. The slit diaphragm bridg-
ing the podocytes contains nephrin, podocin, CD2AP, and nephrin-like proteins NEPH1 and
NEPH2. Contraction and relaxation of the podocytes regulate the glomerular filtration rate
leading to ultrafiltration of water and ion salts into the urinary space. Apart from filtration,
podocytes synthesize the GBM, maintain the shape of the capillary tube, and provide growth
factors for mesangial and endothelial cells. Recent findings demonstrate that cross-talk exists
between the endothelial cells and podocytes, especially during glomerulopathies, indicating a
significant role of these cells in glomerular disease [2].
Glomerulopathies in the USA comprise 90% of patients that need kidney transplantation or
dialysis emphasizing the importance of the development of efficacious drugs to treat injured
glomerular cells [3]. In glomerulopathies such as glomerular nephritis, glomerular sclerosis
and diabetic nephropathy, especially the podocytes are severely affected leading to partial or
complete loss of filtration function [1]. During these diseases, the fenestrations of the glomeru-
lar filtration barrier widen, leading to proteinuria, the hallmark of glomerular diseases. Further,
detachment of the podocyte foot-processes and subsequent loss of the podocytes in urine dra-
matically increases proteinuria. To date, therapeutic intervention to treat podocytopathies is
inadequate. Because of their role in pathological processes of glomerular diseases and their
accessibility through the blood stream of glomerular capillaries, podocytes could be targeted by
systemically applied drug-targeting approaches employing molecular targets specifically
expressed by the diseased podocytes. Although there are few preliminary studies involving
delivery of siRNA and proteins to podocytes [4,5], targeting small molecule therapeutics was
never done. Rapamycin (Sirolimus), a mammalian target of rapamycin (mTOR) inhibitor, is
widely used in the clinic as immunosuppressant to treat patients after kidney transplantation.
However, the prolonged use of rapamycin in kidney transplant patients results in severe pro-
teinuria that leads to the progression of chronic kidney disease and renal failure [6]. Further-
more, it has been shown that mTOR complex 1(mTORC1) is involved in podocyte injury [7].
Using targeted drug delivery systems such as immunoliposomes that accumulate selectively in
designated target cell types, the dosage of rapamycin may potentially be optimized. The selec-
tive delivery of rapamycin in podocytes can minimize the total dose needed and can minimize
the exposure of other cells to this potent mTOR inhibitor, thus potentially reducing the risk for
serious side effects.
In this study, we investigated whether podocytes express inflammation-induced cell adhe-
sion molecules like vascular cell adhesion molecule-1 (VCAM-1). VCAM-1 is a surface-
expressed receptor that can facilitate receptor-mediated endocytosis of nanosized drug carriers.
We used lipid-based nanocarriers called SAINT-O-Somes that were previously shown to
have better intracellular drug release properties than conventional liposomes, and that can tar-
get a particular cell type when harnessed with an antigen-specific antibody [8,9]. Here, we
report that cultured podocytes express VCAM-1 when triggered with TNFα to mimic the
inflammatory condition. Furthermore, as a conceptual proof of targeting drugs to podocytes,
we demonstrated that these cells internalize this type of lipid-based nanocarriers and, finally,
that rapamycin incorporated into VCAM-1-SAINT-O-Somes effectively inhibited cellular
responses in VCAM-1-expressing podocytes.
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(POPC) and 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene gly-
col)-2000] (DSPE-PEG2000) were obtained from Avanti Polar Lipids (Alabaster AL, USA).
Cholesterol (Chol) and N-succinimidyl-S-acetylthioacetate (SATA) were purchased from
Sigma-Aldrich (St. Louis MO, USA). 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine
perchlorate (DiI) was fromMolecular Probes (Leiden, the Netherlands) and 1-methyl-4-(cis-
9-dioleyl)methyl-pyridinium-chloride (SAINT-C18) from Synvolux Therapeutics Inc. (Gro-
ningen, the Netherlands). All chemicals used were of analytical grade unless otherwise stated.
Cell Culture
The generation of the human and mouse conditionally immortalized podocyte cell lines, AB8/
13 and MPC-5, were previously described [10,11]. AB8/13 podocytes were kindly provided by
Dr. Moin A. Saleem (Bristol, UK); Dr. Peter Mundel (Charlestown, USA) kindly provided the
MPC-5 cells. AB8/13 and MPC-5 cells were cultured at 33°C and the cells were differentiated
in 5% CO2 incubator at 37°C for 10–15 days as indicated. The cells were cultured in RPMI
1640 medium containing 1% 100 units/ml penicillin/streptomycin and 1% Insulin-Transfer-
rin-Selenium (ITS) (Invitrogen, Breda, the Netherlands) and 10% fetal bovine serum. For
MPC-5 cells, ITS was excluded and pyruvate (1%) and interferon (10 U IFN-γ/ml) were added
for cell proliferation. For differentiation of MPC-5 cells, medium without IFN-γ was used and
the cells were incubated at 37°C in collagen A (10%)-coated cell culture plates (BD Biosciences,
Breda, the Netherlands). The medium was refreshed at 5-day intervals. On the day of the
experiment, cells were incubated in the absence (quiescent cells) or presence of TNFα (Boeh-
ringer Ingelheim GmbH, Ingelheim am Rhein, Germany) at 10 ng/ml for 24 h, unless stated
otherwise.
Isolation of Primary Podocytes
Male C57bl/6OlaHsd mice (18–23 g) were purchased from Harlan (Zeist, The Netherlands).
Animals were group housed and maintained on a mouse chow diet, in a temperature and light-
dark cycle controlled environment (24°C, 12:12 h). Mice were sacrificed under anesthesia
(inhalation of isoflurane/O2), and organs were collected. All animal experiments were per-
formed according to national guidelines and upon approval of the local Animal Care and Use
Committee of Groningen University (DEC 6106).
Glomeruli from kidneys of 6–8 C57BL/6 mice were isolated based on previously described
anti-CD31bead based endothelial cell preparation [12] with the following modifications. Corti-
ces of the kidneys were minced for 3 min and next incubated at 37°C with collagenase-I (0.2
g% in Dulbecco's phosphate buffered saline (DPBS) with Ca2+/Mg2+; Worthington Biochemical
Corp. Lakewood, NJ, USA) for 45 min. The collagenase/kidney mixture was pushed 15–17
times through a 14 G needle and dripped gently through a 70 μm cut-off cell strainer (BD Phar-
mingen, San Diego, CA). The eluate was spun down at 140 x g for 8 min and the pellet was
resuspended in ~3 ml of bead wash solution (PBS with 0.1% BSA and antibiotic/antimycotic
(1:100) (Sigma) followed by incubation with rat anti mouse-CD31 (BD Pharmingen)-coated
magnetic beads (pre-incubated overnight at 4°C with sheep anti-rat beads; (Dynabeads, Life
Technologies, Bleiswijk, the Netherlands)) for 15 min at room temperature on a rotator. The
anti-CD31 positive cells were separated using a Magnetic Particle Concentrator (Invitrogen)
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and the bead discard was sieved through a 40 μm cut-off cell strainer (BD Pharmingen) to iso-
late glomeruli. The glomeruli on cell strainer were washed with 25 ml of DPBS at 5 ml aliquots.
The glomeruli were next treated with 1 ml of collagenase-I (Worthington Biochemical Corp.)
in DPBS with Ca/Mg for 1 h followed by 10 times titruation using an insulin syringe. The glo-
meruli were obtained by spinning down at 140 x g for 8 min and resuspended in Dulbecco’s
Modified Eagle Medium (DMEM)/F-12 supplemented with 10% FCS, 100 μg/ml streptomycin,
100 U/ml pencillin and Insulin-Transferrin-Selenium (ITS) (podocyte-specific medium) and
seeded in gelatin-coated plates at 37°C for 4–5 days. To eliminate the endothelial cells from the
glomerular outgrowths, anti-ICAM-2 (BD Pharmingen)-coated magnetic beads (pre-incubated
overnight at 4°C with sheep anti-rat beads; Dynabeads) were incubated with trypsin/EDTA
detached glomerular outgrowth cells for 15 min at room temperature on a rotator. The ICAM-
2 positive cells were removed from the glomerular outgrowth cells and the ICAM-2 negative
fraction was seeded in podocyte-specific medium until confluent (2–3 days) at 37°C and RNA
was next isolated for RT-qPCR analysis. Cytospots of the ICAM-2 negative fraction cells were
made on microscope slides for immunostaining by releasing the cells from the tissue culture
plates by trypsinization followed by suspending the cells in podocyte-specific medium.
Gene Expression Studies by RT-qPCR
RNA was isolated from cells using the RNeasy1Mini Plus Kit (Qiagen, Venlo, the Nether-
lands) according to manufacturer’s protocol. The concentration and integrity of RNA were
determined by the NanoDrop1ND-1000 spectrophotometer (Wilmington, DE) and by aga-
rose (1%) gel electrophoresis, respectively. Complementary DNA (cDNA) from respective
RNA samples were generated using SuperScript™ III RNaseH-Reverse Transcriptase (Invitro-
gen), RNaseOut inhibitor (40 U) (Invitrogen) and 250 ng random hexamers (Promega, Leiden,
the Netherlands) in 20 μl total volume. 1 μl of the cDNA product was used for each PCR
reaction.
Human GAPDH (Hs99999905_m1), E-selectin (Hs00174057_m1), VCAM-1
(Hs00365486_m1), WT-1 (Hs01103751_m1) and mouse GAPDH (Mm99999915_g1), synap-
topodin (Mm03413333_m1), WT-1 (Mm01337048_m1) and VCAM-1 (Mm00449197_m1)
primer- probes were purchased as Assay-on-Demand from Applied Biosystems (Nieuwekerk
a/d IJssel, the Netherlands). These primer-probes together with Absolute QPCR Rox Mix
(Thermo Scientific, Landsmeer, the Netherlands) were used in Quantitative (q) PCR per-
formed in ABI PRISM 7900HT Sequence Detector (Applied Biosystems), with two technical
replicates per sample. RT-qPCR and data analysis were performed as described previously [9].
The threshold cycle values (Ct) were obtained by the comparative Ct method and we averaged
the two technical replicate Ct values. The respective genes were normalized to the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), resulting in ΔCt values. The rela-
tive mRNA levels were calculated by 2-ΔCt for respective genes.
Western Blot
AB8/13 cells, differentiated for 15 days at 37°C, treated with TNFα (10 ng/ml) for 4, 8 and 24 h
were lysed by sonication in Radio-Immuno Precipitation Assay (RIPA) buffer (Sigma-Aldrich)
for 1 min. Total protein concentration of the lysate was determined by BCA protein assay
(Thermo Scientific) according to manufacturer’s protocol and equal amounts of lysate were
mixed with SDS-loading buffer. The protein samples were electrophoresed on a SDS-(10%)
PAA gel and transferred to a nitrocellulose membrane followed by blocking with 5% skimmed
milk in PBS for 1 h. The membrane was cut based on the molecular masses of the target pro-
teins followed by incubation with primary antibodies rabbit- polyclonal anti-VCAM-1
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(~100-kDa, Santa Cruz Biotechnology Inc. Heidelberg, Germany), mouse-anti-human synap-
topodin (~74-kDa, Progen), rabbit-polyclonal anti-GAPDH (~37-kDa, Santa Cruz Biotechnol-
ogy Inc.) and/or mouse anti-human actin (~42-kDa, Millipore, Amsterdam, the Netherlands)
for 1 h at room temperature. The membranes were washed three times with PBST and incu-
bated with relevant horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h.
Finally, the membranes were washed and the proteins on the membrane were visualized and
detected using Supersignal West Femto Chemiluminescent Substrate (Thermo Scientific) and a
Gel Doc imaging system equipped with a XRS camera (Bio-Rad).
SAINT-O-Somes Preparation
DiI-Saint-O-Somes (SAINT-O-Somes) were prepared fromMal-PEG2000-DSPE, DSPE-
PEG2000, SAINT-C-18, POPC and cholesterol in a molar ratio of 1:4:18:37:40 in chloroform:
methanol (9:1, v/v) as described previously [9]. DiI, a fluorescent label that incorporates in the
liposome lipid bilayer, was added to the lipid mixture at 0.5 mol% of total lipid. The lipid mix-
ture was dried under reduced nitrogen pressure for 30 min and freeze dried followed by 1 h
hydration in HN buffer (10 mMN-2hydroxyethylpiperazine- N-2-ethanesulfonic acid
(Hepes), 135 mMNaCl) pH 6.7 and 10 times rapid freezing in liquid N2 and thawing in a
water bath at 40°C. The so-formed SAINT-O-Somes were extruded 13 times through polycar-
bonate filters (Costar, Cambridge MA, USA) having a pore size of 50 nm at 40°C, using a high
pressure extruder (Lipex Biomembranes Inc., Vancouver, Canada).
Part of the total SAINT-O-Somes preparation was conjugated with a specific antibody (tar-
geted SAINT-O-Somes), the non-modified SAINT-O-Somes (non-targeted) were used as con-
trol. Mouse anti-human VCAM-1 (IgG1) was purified from supernatant produced by
hybridoma E1/6aa2 as previously described for mouse anti-human E-selectin [9]. The mono-
clonal VCAM-1 antibody-producing hybridoma E1/6aa2 was kindly provided by Dr. M. Gim-
brone Jr. (Harvard Medical School, Boston, MA, USA). The monoclonal mouse anti-human
VCAM-1 antibody was thiolated by SATA and was coupled (0.22 mg of antibody/μmol total
lipid) to a maleimide group present at the distal end of the PEG chain as previously described
[9]. The antibody coupled-SAINT-O-Somes was purified from the free antibody by two rounds
of density-gradient ultra-centrifugation each at 242,000 x g at 4°C for 2 h, and followed by
overnight dialysis at 4°C against HN buffer of pH 7.4.
For the rapamycin-SAINT-O-Somes preparation, POPC, cholesterol, Mal-PEG-DSPE and
SAINT-C-18, were dissolved in chloroform:methanol (9:1, v/v) in a round-bottom flask in a
molar ratio of 1.48:1.6:0.2:0.72, respectively. Desired amounts of rapamycin were simulta-
neously added to the lipid mixture based on the total amount of lipid (20 nmol rapamycin/
μmol total lipid) and a drug-lipid film was created using a rotary evaporator and subsequent
drying under a nitrogen stream. SAINT-O-Somes were hydrated by adding HN buffer followed
by sonication for 10 min and incubation for 1h at room temperature. The extrusion and anti-
body coupling steps were performed as described for VCAM-1-DiI-SAINT-O-Somes. Free
antibody and non-encapsulated rapamycin were removed by passing SAINT-O-Somes
through a PD10 column followed by spinning in a Vivaspin centrifugal concentrator (Sartorius
AG, Aubagne, France) with a molecular weight cut-off membrane of 300-kDa.
Characterization of SAINT-O-Somes
The phospholipid phosphate content of the SAINT-O-Somes was determined by phosphate
assay [13,14]. The mean particle size was measured by NicompTM 380 ZLS particle analyzer.
The polydispersity index of the SAINT-O-Somes was determined by dynamic light scattering
using a Malvern CGS-3 multiangle goniometer (Malvern Instruments Ltd., Worcestershire,
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UK) with a JDS Uniphase 22 mWHe–Ne laser operating at 632 nm, an optical fiber-based
detector and a digital LV/LSE- 5003 correlator. All measurements were performed at a 90°
angle. The zeta-(z) potential of the SAINT-O-Somes was determined by laser doppler electro-
phoresis using a Zetasizer Nano-Z (Malvern Instruments Ltd.). Peterson-Lowry protein assay
was performed to determine the amount of antibody coupled to SAINT-O-Somes. SAINT-O-
Somes was stored at 4°C under argon.
Rapamycin content of the SAINT-O-Somes was determined by high performance liquid
chromatography (Waters Acquity HPLC system, Waters Corporation, Milford, MA, USA)
using a Sunfire C18 column, at a flow rate of 1 ml/min and a column temperature of 60°C. The
isocratic mobile phase was composed of 70% acetonitrile and 30% water, UV detection was
performed at 290 nm.
Size, charge, polydispersity index, the amount of rapamycin encapsulated and the anti-
VCAM-1 antibody coupling efficiencies of antiVCAM-1-rapamycin-SAINT-O-Somes are
listed in Table 1. The coupling of anti-VCAM-1 antibody to rapamycin-SAINT-O-Somes was
determined by Dot-blot as described before [15].
Flow Cytometry
AB8/13 and MPC-5 cells differentiated for 15 days at 37°C were incubated with or without
TNFα (10 ng/ml) for 24 h. The cells were detached from the plates by trypsinization and
divided over FACS tubes and washed once with ice cold FACS buffer (PBS-containing 5%
FCS). Next the cells were incubated with mouse anti-human-VCAM-1 (10 μg/ml) (for AB8/
13) and polyclonal rabbit anti-VCAM-1 antibodies (10 μg/ml) (for MPC-5) for 45 min at 4°C
followed by three washing steps with ice cold FACS buffer (PBS-containing 5% FCS). Control
cells were incubated with mouse anti-rat-IgG2a (Clone OX35, hybridoma supernatant) (5 μg/
ml) antibodies (isotype) and quiescent cells were used as controls. Detection was established by
incubation with a FITC-tagged rabbit anti-mouse IgG Fab2 (Jackson immuno research, PA,
USA) (for AB8/13) and alexa488-tagged goat-anti-rabbit (Life Technologies) (for MPC-5) sec-
ondary antibodies for 30 min at 4°C followed by washing three times with FACS buffer.
Similarly, to determine the association of the anti-VCAM-1-DiI-SAINT-O-Somes, quies-
cent or TNFα (10 ng/ml; 24 h)-activated AB8/13 cells were incubated with either anti-VCAM-
1-DiI-SAINT-O-Somes or DiI-SAINT-O-Somes, all at a concentration of 80 nmol total lipid/
ml for 4 h at 37°C. Quiescent cells incubated with an equivalent volume of HN buffer were
included as control. The cells were finally resuspended in 0.2 ml FACS buffer and analyzed by
flow cytometry (Calibur, BD Biosciences, NJ, USA). The mean fluorescence intensity (MFI)
was obtained after analysis with FlowJoTM software package (Tree Star Inc., OR, USA), version
7.6.5). The MFI values of the cells (TNFα-activated and quiescent) incubated with isotype con-
trol antibodies were subtracted from test samples. Results presented were determined from the
mean of three independent experiments with duplicate incubations per experiment.
Fluorescence Microscopy
For immunofluorescence detection of nephrin and Tie2, cytospots of primary podocytes were
made on a microscope slide. To avoid nonspecific binding of antibodies, blocking with PBS-
Table 1. Characterization of rapamycin-SAINT-O-Somes (n = 3)*.
Samples Size (nm) Charge (mv) Polydispersityindex Rapamycin loading efﬁciency (%)
Anti-VCAM-1-rapamycin- SAINT-O-Somes 128 ± 4 10.8 ± 0.9 0.06 ± 0.01 73 ± 0.7
Rapamycin- SAINT-O-Somes 122 ± 2 11.0 ± 0.3 0.07 ± 0.01 71 ± 1.2
*values represent averages (± sd) of 3 formulations
doi:10.1371/journal.pone.0138870.t001
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containing 1% BSA and 5% FCS was performed at room temperature. Guinea pig anti-mouse
nephrin (Promega), rat anti-mouse Tie2 (Millipore) and rabbit-IgG (SouthernBiotech, Ala-
bama, USA) (control) antibodies were added and incubated for 1 h at room temperature fol-
lowed by incubation with respective secondary fluorescent antibodies Goat anti-guinea pig-
FITC (SouthernBiotech), goat anti-rat-FITC (SouthernBiotech) and goat anti-rabbit-Alexa488
(Life Technologies) for 30 min. The cells were washed three times with PBS after incubation
with primary and secondary antibodies. Finally, the nuclei were stained with 40,6-diamidine-20-
phenylindole dihydrochloride (DAPI) in fluoroshield mounting medium (Abcam, Cambridge,
UK). The cells were visualized and analyzed under a fluorescence microscope (DM RXA, Leica
Microsystems AG, Wetzlar, Germany), and Leica Q600 Qwin software V01.06, respectively.
For fluorescence microscopy detection of DiI-SAINT-O-Somes, AB8/13 cells (16,000 cells/
cm2) were seeded in Lab-Tek chamber slides (NUNC, Rochester, NY) and allowed for 15 days to
differentiate at 37°C with medium refreshed every 5 days. Cells were activated with TNFα (10
ng/ml) for 24 h followed by incubation with anti-VCAM-1-DiI-SAINT-O-Somes and DiI-SAIN-
T-O-Somes, both at a concentration of 80 nmol total lipid/ml for 4 h at 37°C. 10 min before the
end of incubation, the nuclei of the cells were stained with Hoechst 33342 (0.1 mg/ml in serum
free medium; Invitrogen) followed by washing three times with ice cold PBS and one final wash
with ice cold serum-free culture medium. The chamber was removed and a cover slip was placed
on the slide followed by sealing with nail polish. The microscopic images were taken within 1 h.
Cell Viability Assay
Effects of rapamycin and rapamycin-SAINT-O-Somes on cell viability of AB8/13 cells were
determined by Sulforhodamine B (SRB) colorimetric assay [16]. AB8/13 cells (15 days differenti-
ated at 37°C; 5000 cells/cm2) were either activated with TNFα (10 ng/ml) for 24 h or incubated
in control medium (non-activated cells). Free rapamycin, rapamycin-SAINT-O-Somes and anti-
VCAM-1-rapamycin-SAINT-O-Somes were added to triplicate wells at final concentrations cor-
responding to 8 or 32 μM rapamycin after which the cells were incubated for an additional 24 h
at 37°C. Cells were washed once with PBS and fixed by addition of 10% (wt/vol) Trichloroacetic
acid (TCA) at 4°C for 1 hour, followed by staining with 0.4% SRB stain in 1% acetic acid for
30min. Excess non-bound SRB dye was removed by multiple washings with 1% acetic acid after
which the cells were dried at room temperature. The protein-bound dye was dissolved in unbuf-
fered 10 mMTris for 30 min and OD values were measured at 490–550 nm with a Spectrostar
microplate reader. The values obtained were normalized versus control cells treated with TNFα.
Wound Healing Assay
Confluent 6-well culture plate with differentiated AB8/13 cells were incubated in the absence
or presence of TNFα (10 ng/ml; 24 h) followed by treatment with free rapamycin, rapamycin-
SAINT-O-Somes and anti-VCAM-1-rapamycin-SAINT-O-Somes at a concentration of 10
nmol/ml. After 12 h incubation with the different formulations, a scratch was made with a ster-
ile 200 μl pipette tip followed by a one-time wash with PBS after which cells were refreshed
with fresh medium. The wound closure was followed in time for the next 24 h with images
taken at 0, 6 and 24 h time points. The extent of wound closure was determined by quantifying
cell migration towards the wound using ImageJ.
Statistical Analysis
Statistical analysis of the results was performed by two-tailed unpaired Student's t-test or one-
way ANOVA. p-values<0.05 were considered to be significant. Data were analyzed with
Graphpad prism (Graphpad software 5.0b, San Diego CA, USA).
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Results, Discussion, and Conclusions
To investigate the possibilities of using VCAM-1 as a molecular target to deliver drugs specifi-
cally (in)to podocytes, we initiated an in vitro study using the human conditionally immortal-
ized podocyte cell line AB8/13 [10]. These cells proliferate at 33°C and differentiate to the
podocyte phenotype in 10–15 days at 37°C. In order to establish the differentiation of AB8/13
cells into a podocyte phenotype, mRNA and protein expression of the podocyte-specific mark-
ers (Wilms’s Tumor-1 (WT-1) and synaptopodin) were analyzed after 15 days at 37°C. Differ-
entiated AB8/13 cells expressed both WT-1 and synaptopodin, confirming AB8/13 as
podocytes (S1 and S2 Figs).
TNFα Exposure Induces the Expression of VCAM-1 in Differentiated
AB8/13 Podocytes
To study the prospects of using adhesion molecule VCAM-1 as a molecular target for podo-
cyte-specific drug delivery purposes, mRNA was isolated from both TNFα (10 ng/ml; 4 h)-acti-
vated and quiescent AB8/13 cells up to 15 days of differentiation at 37°C. Gene expression
levels of VCAM-1 were compared to the housekeeping gene GAPDH. VCAM-1 was expressed
by podocytes and the expression was significantly upregulated by TNFα (Fig 1A). Under the
conditions studied, the expression of VCAM-1 gradually increased with the differentiation
time of the cells and was at its maximum at 15 days of differentiation (Fig 1A). An approxi-
mately 4-fold increase in VCAM-1 mRNA expression was observed in the presence of TNFα
when compared to quiescent cells.
Analysis of VCAM-1 protein expression in the differentiated AB8/13 cells corroborated the
mRNA data that in the absence of TNFα, there is basal expression of VCAM-1 and that the
expression significantly increases in the presence of TNFα (Fig 1B and 1C). To confirm the
expression of VCAM-1 protein by podocytes also flow cytometry was performed. Fig 1C shows
that anti-VCAM-1 antibodies bound to both activated and quiescent cells. There is a 3-fold
higher expression of VCAM-1 in TNFα-activated podocytes compared to quiescent cells (Fig
1C). The binding of VCAM-1 specific antibodies to quiescent cells can be attributed to the
basal expression of VCAM-1 in this condition. These results indicate that VCAM-1 can be
used as a molecular target to address inflammation activated podocytes using nanocarriers.
VCAM-1 Is Also Expressed in a Mouse Podocyte Cell Line and Primary
Mouse Podocytes
We investigated the expression of VCAM-1 both in a conditionally immortalized mouse podo-
cyte cell line (MPC-5) that was differentiated for 12 days at 37°C and in primary mouse podo-
cytes. TNFα was added to the incubation during the last 24 h before isolation of mRNA or
protein. RT-qPCR analysis of podocyte-specific markers synaptopodin and WT-1 showed the
expression of both genes confirming MPC-5 cells as podocytes (S3 Fig). Similar to AB8/13
cells, MPC-5 cells expressed VCAM-1 and the expression was significantly upregulated in the
presence of TNFα (Fig 2A). Western blot analysis and flow cytometry of MPC-5 cells are in
accordance with the gene expression results, showing significant VCAM-1 protein levels in
these cells upon activation with TNFα (Fig 2B and 2C).
Primary mouse glomerular cells grew to confluency within 4–5 days of incubation at 37°C
in podocyte-specific medium (Fig 3A), after which the non anti-ICAM-2 beads sorted popula-
tion was seeded in podocyte-specific medium. Cytospots from these ICAM-2 negative fractions
were stained with podocyte and endothelial cell-specific antibodies. Immunofluorescence anal-
ysis showed specific detection of the podocyte-specific marker nephrin confirming that the
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cultured cells had a podocyte-like phenotype (Fig 3B). In contrast, cytospots stained for Tie2
that is restrictedly expressed by endothelial cells showed no fluorescence indicating that there
was no contamination with endothelial cells (Fig 3C and 3D). Primary podocytes were either
grown in quiescence or activated by TNFα for 6 h and RNA was isolated to determine the
expression of podocyte and endothelial markers and VCAM-1. In accordance with the data
Fig 1. VCAM-1 is expressed in AB8/13 cells and the expression is increased upon TNFα-activation. (a)
RT-qPCR analysis of human VCAM-1 mRNA expression. The AB8/13 cells were differentiated for 0, 5, 10,
and 15 days at 37°C and treated with TNFα (10 ng/ml) for 4 h. (b) Western blot analysis of VCAM-1
(~110-kDa) and actin (~42-kDa) (loading control) proteins expression in cell lysate of AB8/13 cells, 15 days
differentiated at 37°C in the absence (-) or presence (+) of TNFα for various time points. (c) FACS analysis of
VCAM-1 protein in TNFα-activated (10 ng/ml; 24 h) and quiescent AB8/13 cells incubated with mouse anti-
human-VCAM-1 for 45 min at 4°C followed by incubation with fluorescently-labelled secondary antibody.
*p <0.001.
doi:10.1371/journal.pone.0138870.g001
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obtained with AB8/13 cells and MPC-5 cells, VCAM-1 was also expressed in mouse primary
podocytes and the expression was upregulated in the presence of TNFα (Fig 3E). RT-qPCR
analysis showed the expression of podocyte-specific genes (WT-1 and synaptopodin) confirm-
ing these primary cells as podocytes (S4 Fig). There is minute expression of the endothelial-spe-
cific genes CD31 and VEcadherin confirming that there is hardly any contamination of
glomerular endothelial cells in the primary podocyte culture (S4 Fig). Since the yield of primary
podocytes after isolation from mouse kidneys is limited, we only performed low cell number
Fig 2. VCAM-1 is expressed by the mouse podocyte cell line MPC-5. (a) mRNA expression of VCAM-1 in
the absence (-) or presence (+) of TNFα (10 ng/ml; 24 h) as analyzed by RT-qPCR analysis. (b) Western blot
analysis of protein extracts of MPC-5 cells that were incubated in the absence (-) or presence (+) of TNFα (10
ng/ml; 24 h) prior to harvesting. M and control indicate respectively, pre-stained molecular weight marker and
positive control (HUVEC activated with LPS for 6 h). (c) FACS analysis of VCAM-1 expression by MPC-5
cells using anti-VCAM-1 antibody by flow cytometry. *p <0.001.
doi:10.1371/journal.pone.0138870.g002
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requiring gene expression analysis and immunofluorescence of VCAM-1 in primary
podocytes.
Based on these in vitro gene and protein expression results in AB8/13, MPC-5, and primary
mouse podocytes, we concluded that VCAM-1 is expressed by podocytes and that the expres-
sion was significantly upregulated by activation of the cells with the pro-inflammatory cytokine
TNFα. This led us to hypothesize that VCAM-1 can be exploited as a molecular target to spe-
cifically deliver drugs (in)to podocytes using a nanocarrier system, especially since VCAM-1
receptors were shown to be internalized by cells via clathrin-mediated endocytosis [17]. This is
Fig 3. VCAM-1 is expressed in primary mouse podocytes. (a) Phase-contrast view of glomerular outgrowths of isolated glomeruli frommouse kidney, 2
days after seeding in podocyte-specific medium. Immuno-staining of cytospots of the ICAM-2 negative fraction after ICAM-2 re-beading, detecting nephrin
(b), while the endothelial marker Tie2 (c) is not detected. Panel (d) shows background staining with control rabbit-IgG antibodies (and does not detect
anything). Antibodies that specifically bound to the cells are stained in green. Nuclei were stained in blue with DAPI. (e) VCAM-1 mRNA expression in mouse
primary podocytes in the absence (-) or presence (+) of TNFα, as determined by RT-qPCR. Data are presented as mean values +/- sd, n = 3 from three
independent experiments.
doi:10.1371/journal.pone.0138870.g003
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a prerequisite for an efficient nanocarrier to successfully deliver its contents inside its target cell
[18].
Association of Anti-VCAM-1-DiI-Saint-O-Somes with Inflammation
Activated AB8/13 Podocytes
To deliver therapeutic compounds into podocytes, we used a SAINT-based lipid drug carrier
system called SAINT-O-Somes with anti-VCAM-1 antibodies coupled to the distal end of the
polyethylene glycol molecules to make them inflammation activated podocyte specific. To
investigate the binding and association by the podocytes, SAINT-O-Somes were labeled with
DiI in the lipid bilayer. The diameter of DiI-SAINT-O-Somes and anti-VCAM-1-DiI-SAIN-
T-O-Somes was 95+/- 2 and 115+/- 11 nm, respectively. 45+/- 3 of anti-VCAM-1 antibodies
were coupled per μmol total lipid of SAINT-O-Somes, which was comparable to earlier studies
in which siRNA was incorporated in anti-VCAM-1 antibody harnessed SAINT-O-Somes [8].
Anti-VCAM-1-DiI-SAINT-O-Somes (targeted) and DiI-SAINT-O-Somes (non-targeted)
were incubated for 4 h with quiescent and TNFα-activated, 15 days differentiated AB8/13 cells
at 37°C. Fluorescence microscopy analysis showed association of anti-VCAM-1-DiI-SAIN-
T-O-Somes, both in quiescent and TNFα-activated podocytes, with the association with acti-
vated cells being much higher (Fig 4C and 4D). In contrast, non-targeted-DiI-SAINT-O-
Somes were hardly associated with either quiescent or TNFα-activated cells (Fig 4A and 4B),
indicating specificity of targeted-DiI-SAINT-O-Somes for podocytes.
These results were supported by the flow cytometry results, which showed that association
of anti-VCAM-1-DiI-SAINT-O-Somes to TNFα-activated podocytes was increased almost
3-fold and more than 150-fold compared to quiescent cells and cells incubated with non-tar-
geted-SAINT-O-Somes, respectively (Fig 4E). The non-targeted-SAINT-O-Somes were hardly
associated with the AB8/13 cells, either in the absence or presence of TNFα. These results dem-
onstrate proof-of-concept of targeting podocytes using anti-VCAM-1 nanocarriers.
Effect of Anti-VCAM-1-rapamycin-SAINT-O-Somes on Inflammation
Activated AB8/13 Podocytes
It has been proposed that mTOR is involved in podocyte injury [7]. The delivery of mTOR
inhibitor rapamycin to podocytes hence will be an attractive approach to treat podocyte injury.
One of the techniques to study rapamycin effects in cells is studying migration of the cells.
Rapamycin was encapsulated in the lipid-bilayer of the anti-VCAM-1-SAINT-O-Somes and
control SAINT-O-Somes. The coupling of VCAM-1 specific antibody to rapamycin-SAIN-
T-O-Somes was confirmed by Dot-blot assay using anti-VCAM-1 antibody detection of the
protein (S5 Fig). The cytotoxicity of rapamycin and anti-VCAM-1-rapamycin-SAINT-O-
Somes was analyzed (S6 Fig), demonstrating that incubation of AB8/13 podocytes with free
or targeted liposomal rapamycin did only slightly affect cell viability at 8 μM and 32 μM
rapamycin.
To test the effects of drug loaded anti-VCAM-1-rapamycin-SAINT-O-Somes and compare
these with drug loaded non-targeted-SAINT-O-Somes and free drug, a wound healing assay
was performed. Light microscopic images from the wound healing assay show that AB8/13 cell
migration was almost completely inhibited in TNFα-activated cells treated with anti-VCAM-
1-rapamycin-SAINT-O-Somes indicating a cell migration inhibitory effect of rapamycin when
applied in the SAINT-O-Somes formulation (Fig 5A). We also observed partial inhibition of
cell migration in cells that had not been pretreated with TNFα which is most likely due to the
basal expression of VCAM-1 in these cells (Fig 4). Free rapamycin and non-targeted-SAIN-
T-O-Somes loaded with rapamycin showed partial response in TNFα pretreated cells, but
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these effects were less pronounced as compared to the anti-VCAM-1-rapamycin-SAINT-O-
Somes (Fig 5A). Quantification of closure of the wound area showed a 3-fold inhibition of the
Fig 4. Anti-VCAM-1-DiI-Saint-O-Somes bind to AB8/13 cells.DiI-SAINT-O-Somes (a, b) and anti-VCAM-1-DiI-SAINT-O-Somes (c, d) were incubated for
4 h at 37°C with AB8/13 cells in the absence (-) (A, C) or presence (+) (b, d) of TNFα (10 ng/ml; 24 h). The nuclei were stained blue with Hoechst 33342.
Original magnification 200x. (e) Quantification of binding of anti-VCAM-1-DiI-SAINT-O-Somes or DiI-SAINT-O-Somes to AB8/13 cells. Cells incubated in
equal volumes of HN buffer were taken as controls and their values were subtracted from test samples. The mean fluorescence intensity (MFI) was
determined by FACS and analyzed by FlowJoTM. *p <0.001.
doi:10.1371/journal.pone.0138870.g004
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wound closure in 24 h by the targeted formulation when compared to control cells (Fig 5B).
The observed cell migration inhibitory effects are likely due to the inhibition of the actin cyto-
skeleton by rapamycin [19].
Together these experiments provide conceptual proof that VCAM-1 can be employed as a
molecular target to deliver therapeutic compounds into injured podocytes. As mentioned ear-
lier, the fenestrations of the glomerular barrier widen during podocytopathies enabling the
nano-sized carriers such as liposomes to reach injured podocytes. In glomerular diseases, not
only podocytes but rather all GFB cells, kidney arterioles and venules are injured leading to the
expression of various adhesion molecules including VCAM-1. Earlier studies demonstrate that
VCAM-1 expression is upregulated in vascular endothelial cells under inflammatory
Fig 5. Effect of anti-VCAM-1-rapamycin-SAINT-O-Somes on AB8/13 cells. (a) A scratch was made into confluent cell cultures of AB8/13 in the absence
(-) or presence (+) of TNFα (10 ng/ml; 24 h). These cells were first treated with HN buffer (control), free drug, rapamycin-SAINT-O-Somes and anti-VCAM-
1-rapamycin-SAINT-O-Somes for 12 h, after which a wound was induced and the wound closure was followed in time up to 24 h. (b) The number of cells that
had migrated into the scratch area (═) were quantified from two independent experiments by ImageJ.
doi:10.1371/journal.pone.0138870.g005
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conditions [8,20,21]. Hence, one can expect that rapamycin loaded anti-VCAM-1-SAINT-O-
Somes will be internalized by inflammation triggered endothelial cells, similar to previously
reported siRNA loaded anti-VCAM-1-SAINT-O-Somes [8, 22]. The expression of VCAM-1
on (subsets of) endothelial cells and on activated podocytes has obviously implications for tar-
geted drug delivery. Although one would like to differentiate between uptake in endothelial cell
and podocytes from a scientific proof-of-concept point-of-view, such an exploration in animal
models may pose several technical hurdles. First, renal function should largely be preserved in
the early stages of the experimental animal model which infers that only a subset of glomeruli
(and also the podocytes and endothelial cells) will be disease affected. Podocyte- and endothe-
lium-associated expression of VCAM-1 will furthermore strongly depend on the progression
of renal disease in the experimental model. We have earlier demonstrated that the expression
of VCAM-1 in glomerular endothelial cells is low in experimental glomerulonephritis, likely
because of high microRNA 126 levels which have been shown to down regulate VCAM-1 pro-
tein expression [23]. Podocytes and endothelial cell only constitute a small percentage of the
total kidney mass, and accumulation of anti-VCAM-1-SAINT-O-Somes in these respective cell
types can be demonstrated by immunohistochemical staining. This strategy proved successful
for demonstrating in vivo glomerular endothelial cell targeting by anti-E-selectin liposomes
[24]. Identification of the cell type involved in glomerular accumulation of the nanocarriers
can be done by double staining with podocyte- or endothelium-specific cell markers to get
answers on which cell type actually has accumulated the immunoliposomes. Moreover, since
both these cell types play an important role in inflammatory processes in the kidney we
hypothesize that drug delivery to these cell types may lead to additive therapeutic effects, pro-
viding that the delivered drug has beneficial effects in both cell types. Rapamycin may be a
good candidate for such a nanocarriers-based approach. We presume that an anti-VCAM-
1-coated nanocarrier could be an option to therapeutically address more than one cell type
under inflammatory conditions in kidney diseases. Establishing podocyte targeting in vivo in a
relevant disease model is an obvious and interesting perspective for future research.
Supporting Information
S1 Fig. Wilm’s Tumor-1 (WT-1) is expressed by AB8/13 cells. AB8/13 cells were allowed to
differentiate for 15 days at 37°C and RNA was isolated from cells incubated in the absence or
presence of TNFα (10 ng/ml, 24 h). WT-1 mRNA expression relative to GAPDH was analyzed
by RT-qPCR. Data are presented as mean values +/- sd, n = 3 from three independent experi-
ments.
(TIF)
S2 Fig. AB8/13 cells express the podocyte-specific marker synaptopodin. Synaptopodin
detection on a Western blot loaded with cell lysates of AB8/13 cells, 15 days differentiated at
37°C in the absence (-) or presence(+) of TNFα for 24 h (10 ng/ml), respectively. The molecu-
lar mass (kDa) of pre-stained marker (M) is indicated at the left hand side of the blot. 6 h LPS-
activated HUVEC cell lysate and mouse kidney lysate were used as negative and positive con-
trols, respectively. Arrows indicate the bands of synaptopodin and GAPDH as loading control.
(TIF)
S3 Fig. Mouse podocyte cell line (MPC-5) expresses podocyte markers.mRNA expression of
mouse podocyte-specific markers synaptopodin andWT-1 in the absence (-) or presence (+)
of TNFα (10 ng/ml; 24 h) relative to mouse GAPDH, as analyzed by RT-qPCR analysis. Data
are presented as mean values +/- sd, n = 3 from three independent experiments.
(TIF)
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S4 Fig. WT-1 and synaptopodin expression by primary mouse podocytes. RNA was isolated
from the ICAM-2 negative glomerular cell fraction and analyzed for the mRNA expression of
podocyte (WT-1 and synaptopodin) and endothelial (CD31 and VEcadherin) cell-specific
markers, relative to mouse GAPDH, using RT-qPCR. Data are presented as mean values +/-
sd, n = 3 from three independent isolates.
(TIF)
S5 Fig. Dot-blot assay to demonstrate anti-VCAM-1 antibody conjugation to rapamycin-
SAINT-O-Somes. Anti-VCAM-1-rapamycin- SAINT-O-Somes and rapamycin-SAINT-O-
Somes were loaded in dilutions ranging from 10x-80x. The successful coupling of anti-VCAM-
1 antibody to rapamycin-SAINT-O-Somes was confirmed using fluorescent secondary anti-
body detecting the anti-VCAM-1 antibody (green). Rapamycin-SAINT-O-Somes without
anti-VCAM-1 antibody conjugated did not yield a signal.
(TIF)
S6 Fig. Effect of rapamycin on viability of AB8/13 cells. Cell viability of AB8/13 podocytes,15
days differentiated at 37°C, incubated with rapamycin formulations for 24h. Cell viability was
assessed by SRB staining and normalized to TNFα treated control cells. Data shown are mean
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